Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
Novartis
Eastern Cooperative Oncology Group
Children's Oncology Group
Baylor College of Medicine
SWOG Cancer Research Network
Goethe University
Centre Leon Berard
Novartis
American University of Beirut Medical Center
Karolinska University Hospital
OHSU Knight Cancer Institute
Medical College of Wisconsin
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Sir Mortimer B. Davis - Jewish General Hospital
Institute of Hematology & Blood Diseases Hospital, China
University College, London
Shandong University
University of Liverpool
University of Jena
Ascentage Pharma Group Inc.
Gruppo Italiano Malattie EMatologiche dell'Adulto
Il-Yang Pharm. Co., Ltd.
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Australasian Leukaemia and Lymphoma Group
Novartis
OHSU Knight Cancer Institute
Sumitomo Pharma America, Inc.
Bristol-Myers Squibb
Rennes University Hospital
Jewish General Hospital
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
University of Washington
Milton S. Hershey Medical Center
Jiangsu Hansoh Pharmaceutical Co., Ltd.
National Cancer Institute (NCI)
Gruppo Italiano Malattie EMatologiche dell'Adulto
Gruppo Italiano Malattie EMatologiche dell'Adulto
Institut Bergonié
Novartis
Novartis
Novartis
Pfizer
Mansoura University
Institut Bergonié
Dana-Farber Cancer Institute
National Research Center for Hematology, Russia